Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma

This is an open-label, multicenter Phase I/II clinical study conducted in participants with unresectable locally advanced or metastatic melanoma, aiming to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of JMT108 Injection in this population. The study consists of Phase I and Phase II (including Phase IIa and Phase IIb), where Phase I is the dose-escalation stage, Phase IIa is the dose-expansion stage, and Phase IIb is the cohort-expansion stage.

Trial Details

NCT ID
NCT07280832
Phase
PHASE1 / PHASE2
Sponsor
Shanghai JMT-Bio Inc.
Status
RECRUITING
Cancer Type
Melanoma
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Age≥18 years old.
  • Histologically or cytologically confirmed unresectable locally advanced or metastatic melanoma.
  • Participants with unresectable locally advanced or metastatic melanoma who have failed prior standard treatment or have no available standard treat…
  • According to the response evaluation criteria for solid tumors (RECIST 1.1), having at least one measurable lesion.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →